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Abstract K-Tocopherol (the major vitamin E component)
regulates key cellular events by mechanisms unrelated with its
antioxidant function. Inhibition of protein kinase C (PKC)
activity and vascular smooth muscle cell growth by K-tocopherol
was first described by our group. Later, K-tocopherol was shown
to inhibit PKC in various cell types with consequent inhibition of
aggregation in platelets, of nitric oxide production in endothelial
cells and of superoxide production in neutrophils and macro-
phages. K-Tocopherol diminishes adhesion molecule, collagenase
and scavenger receptor (SR-A and CD36) expression and
increases connective tissue growth factor expression. , 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Biochemistry textbooks describe vitamin E as a lipid solu-
ble, chain breaking radical scavenger. This feature has been
described in great detail but it appears not to include all of the
properties of the di¡erent tocopherols comprised by the def-
inition of vitamin E. Several tocopherols have special proper-
ties, which are unrelated to their antioxidant capacity. The
present article is devoted to the description of those molecular
aspects of the most potent vitamin E component, K-tocoph-
erol, that cannot be accounted for by its antioxidant power.
2. K-Tocopherol protects against a number of disorders
Mutations of the K-tocopherol transfer protein (K-TTP)
gene lead to a reduced K-tocopherol concentration in plasma
and tissues and eventually to a lethal syndrome, ataxia with
vitamin E de¢ciency (AVED) [1]. Vitamin E supplementation
has protective e¡ects against a number of disorders besides
AVED, in particular atherosclerosis, ischemic heart disease
and di¡erent tumors [2^4].
3. Selective uptake of K-tocopherol
The ¢rst example of a non-antioxidant reaction involving
K-tocopherol is given by its uptake in the liver [5] where
chylomicron remnants deliver it to the 32 kDa K-TTP. This
protein has a higher a⁄nity for K-tocopherol relative to the
other tocopherols and tocotrienols. Some of the eight di¡erent
side-chain isomers of racemic tocopherol are excluded from
the plasma and secreted with the bile [6]. Relative a⁄nities of
tocopherol analogs for K-TTP, calculated from the degree of
competition for the K form, are as follows: K-tocopherol,
100%; L-tocopherol 38%; Q-tocopherol 9%; N-tocopherol
2%; K-tocopherol acetate 2%; K-tocopherol quinone 2% [7].
The K-tocopherol transfer protein facilitates K-tocopherol
incorporation into very low density lipoproteins that deliver
it to peripheral cells [8].
4. Speci¢c intracellular K-tocopherol binding proteins
K-TTP is mainly expressed in the liver, in some parts of the
brain [9], in the retina [10], lymphocytes and in low amounts
in ¢broblasts [11], as well as in the labyrinthine trophoblast
region of the placenta [12], where it may be responsible for
regulating local K-tocopherol concentrations. Recently, a fam-
ily of cellular tocopherol associated proteins (TAPs) has been
identi¢ed [13]. TAP1 binds K-tocopherol better than the other
tocopherols [14]. Present in all cells, TAPs may be speci¢cally
involved in intracellular tocopherol tra⁄c, for example be-
tween membrane compartments and the plasma membrane,
similar to the yeast secretory protein (sec14p). TAPs show
GTPase activity and may modulate reactions like phospholip-
id/tocopherol signalling, phospholipid/tocopherol secretion or
optimizing the tocopherol composition of membranes. TAP1
has recently been described as a cytosolic squalene transfer
protein and enhances cholesterol biosynthesis by activating
the enzyme squalene epoxidase [15], suggesting a possible
involvement of TAPs in the transport of a number of hy-
drophobic compounds in competition with K-tocopherol
(Fig. 1). Thus, these proteins may make K-tocopherol a suit-
able regulator in di¡erent cellular reactions. A further role
for TAP1 has been suggested by Yamauchi’s [14] group. Nu-
clear translocation of TAP1 and transcriptional activation
have been suggested to occur under the in£uence of K-tocoph-
erol.
Another tocopherol binding protein also preferentially in-
teracts with K-tocopherol and may be responsible for intra-
cellular distribution of K-tocopherol [16].
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5. Reactions of K-tocopherol at cellular level
Protein kinase C (PKC) inhibition is the cause of vascular
smooth muscle cell proliferation inhibition caused by K-to-
copherol [17,18]. This event takes place at concentrations of
K-tocopherol considered optimal in human beings [19]. L-To-
copherol is per se ine¡ective but prevents the inhibition in-
duced by K-tocopherol (Fig. 2). The radical scavenging prop-
erties of these two molecules are essentially equal [20] ; thus
the e¡ect of K-tocopherol cannot be attributed to its antioxi-
dant properties. This same phenomenon has been established
in monocytes, macrophages, neutrophils, ¢broblasts and me-
sangial cells [21^27]. In endothelial cells, thrombin-induced
PKC activation and endothelin secretion are inhibited by
K-tocopherol but not by L-tocopherol [28]. By inhibiting
PKC in monocytes, the phosphorylation and translocation
of the cytosolic factor p47 (phox) are also inhibited. Conse-
quently, NADPH-oxidase assembly and superoxide produc-
tion are impaired [29].
K-Tocopherol does not produce inhibition of recombinant
PKC in vitro, thus excluding that the e¡ect observed in cells is
caused by tocopherol-protein interaction. K-Tocopherol does
not inhibit PKC expression either. Inhibition of PKC activity
by K-tocopherol is due, at cellular level, to dephosphorylation
of the protein [30]. Protein phosphatase 2A (PP2A) can be
activated by K-tocopherol and causes dephosphorylation of
PKC [30^32].
5.1. Transcriptional regulation by K-tocopherol
A non-antioxidant reaction induced by K-tocopherol causes
up-regulation of K-tropomyosin expression by K-tocopherol;
also in this case L-tocopherol is not e¡ective [33]. Human skin
¢broblasts exhibit an age-dependent increase of collagenase
expression that can be diminished by K-tocopherol [34]. Diet-
ary K-tocopherol modulates the expression of the liver K-TTP
and of its mRNA [35]. Scavenger receptors are particularly
important in the formation of atherosclerotic foam cells [36]
and disruption of CD36 protects against atherosclerotic le-
sion. In smooth muscle cells and monocytes/macrophages,
the oxidized LDL scavenger receptors SR-A and CD36 are
transcriptionally down-regulated by K-tocopherol but not by
L-tocopherol [37^39]. Recently (Villacorta et al., unpublished),
the connective tissue growth factor transcription has been also
found to be under the positive control of K-tocopherol.
5.2. Inhibition of monocyte-endothelial adhesion
Monocytes and neutrophils enriched with K-tocopherol de-
crease their adhesiveness both in vivo and in vitro [40,41] due
to the down-regulation of adhesion molecule expression
[42,43].
5.3. Inhibition of platelet adhesion and aggregation
K-Tocopherol inhibits aggregation of human platelets by a
PKC-dependent mechanism, both in vitro and in vivo [23],
and delays intra-arterial thrombus formation [44].
It is generally accepted that K-tocopherol exerts its inhibi-
tory action on a number of cell reactions by interacting pri-
marily at the level of PKC. However, the expression of several
genes, such as CD36 [38], SR class A [45], collagenase [34],
ICAM-1 [46] and some integrins [47], appears to be regulated
by K-tocopherol in a PKC independent way. There are also
data indicating that K-tocopherol activates PP2A [30] and that
it inhibits 5-lipoxygenase [48] and cyclooxygenase [49]. These
phenomena are still not fully characterized.
6. Conclusions
The inhibition of a number of important cellular reactions
by K-tocopherol can be traced back to its e¡ect on PKC. In its
turn, inhibition of PKC has been shown to be due to the
activation of the protein phosphatase PP2A. The inhibition
of PKC in many, but not all cells, may be relevant in explain-
ing the anti-atherosclerotic and anti-tumor e¡ects of this vi-
tamin in vivo. Furthermore, the expression of a number of
genes has been found to be under the non-antioxidant control
of K-tocopherol, suggesting a new level of action of K-tocoph-
erol in protection against disease. This compound, uniquely
important for the human body, cannot be considered merely a
simple antioxidant. A special conserved protein for its uptake
and a family of proteins for its cellular distribution and action
point to the need of the organism to select and protect this
compound against radical damage and immediate metabolic
degradation rather than use it to shield other cellular compo-
Fig. 1. Suggested mechanism of K-tocopherol modulated enzyme ac-
tivation by phospholipid^TAP complexes.
Fig. 2. PKC inhibition by K-tocopherol and not by L-tocopherol.
Quiescent cells were re-stimulated to enter into the G1-phase by
adding 10% fetal calf serum in the presence or absence of K-toco-
pherol or L-tocopherol (50 WM). After 7 h cells were permeabilized
and PKC was measured. Phorbol myristate acetate (100 nM) was
added 60 min before assaying PKC activity. The basal kinase activ-
ity was subtracted in all samples and only the phorbol myristate
acetate stimulated activity was considered [18].
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nents. Thus, the network of antioxidant systems of the organ-
ism should be considered not only valuable for the protection
of DNA, lipid and protein against oxidative damage, but also
for the protection of K-tocopherol (Fig. 3). Special non-anti-
oxidant functions have been attributed more recently to Q-to-
copherol [50], suggesting a general project of nature to utilize
the compounds de¢ned together with vitamin E in precise and
unique non-antioxidant reactions.
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Fig. 3. Scheme of the network of cell antioxidants: they protect not
only DNA, protein and lipid but also K-tocopherol against radical
damage.
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